Fischer Imaging
This article was originally published in The Gray Sheet
Executive Summary
Restatement of financial results for fiscal year 2000 and the first quarter of 2003 may be subject to "further adjustment," pending an independent audit, the firm says. A four-month review of prior accounting practices initiated by the board had uncovered "inaccuracies" and internal control failures (1"The Gray Sheet" June 23, 2003, p. 19)...
You may also be interested in...
Fischer Receives SEC Subpoena, Prepares To Release Restated 2002 Results
Fischer Imaging will restate financial results from fiscal years 2000 to 2002 to reflect product sales recorded on the date equipment was installed, rather than the shipment date
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.